#cannabisaficionado

Cannabis

Discovering Cannabis Unicorns in a Phenotype Mega-Hunt

Nathaniel Pennington from Humboldt Seed Company explains his phenotype mega-hunt — the search for the best and brightest of the cannabis genome.

Published

on

Phenotype Mega-Hunt
PHOTO | Humboldt Seed Company
Advertisement Back2Grow Advertisement

The science of cannabis genetics has existed in a hazy realm of illegality and prohibition-derived stigma for nearly a century. Relegated by the first anti-pot laws in the United States that appeared in 1913 in states such as Indiana, Maine, and Wyoming, cannabis cultivators seeking connoisseur-grade examples of the art have traditionally worked in cloistered isolation, mired in the ignorance of pseudo-science and urban legend.

This generations-old underground culture of ultra-discreet operation has resulted in a nascent legal industry that suffers a gross lack of hard research and peer-reviewed science. Unfortunately, most cannabis breeders operate in a desperate state of self-reliance, employing guesswork and questionable genetic material.

Newly legal adult use markets across North America—including California, Canada, Massachusetts, and Nevada—are finally allowing researchers to seriously investigate cannabis genetics and breeding. This, in turn, is helping support the natural industry-wide desire to introduce novel products to market that address specific consumer preferences or patient medical needs.

Playing Catch Up

One example of the new generation of entrepreneurial researchers attempting to push the boundaries of cannabis genetics is Nathaniel Pennington, CEO and founder of Humboldt Seed Company (HSC).

As a biologist and geneticist focused on the development of premium cannabis genetics, Pennington has for years been obsessed with creating the best possible seeds and clones to support both commercial cultivators and self-sustaining gardeners.

Over the past almost two decades, the pioneering company he founded in 2001 has gathered a large volume of data regarding the science of superior cannabis genetics, with a focus on varieties that offer rare terpene and cannabinoid profiles. The company’s Blueberry Muffin strain, a decade in the making and increasingly popular in West Coast dispensaries, was described by Leafly as the most accurately named strain on the market.

Blueberry Muffin PHOTO | Humboldt Seed Company

Despite these successes, Pennington employs a data-driven management style steeped in reality. “We have so much catch up work to do in cannabis breeding. In Humboldt, we’re starting over in a proper way,” he said during an exclusive interview with Cannabis Aficionado from his cannabis farm-come-genetics laboratory in Humboldt County, California.

Not satisfied with the state of cannabis genetics in the Golden State (the world’s sixth largest economy and one of the newest entrants to the legal adult use cannabis market), Pennington began investigating ways to bring together the brightest minds in cannabis cultivation and genetics research. His goal? To leverage his experience in genome annotation and DNA markers affecting plant behavior to push forward the science of commercial ganja genetics.

The Phenotype Mega-Hunt

Headquartered in the heart of Northern California’s fabled Emerald Triangle, Pennington’s response to California’s new cannabis legalization — and the threats and opportunities that it presents for small and mid-sized farmers in the region — has been to hunt and breed the best genetics in use for local farms and nurseries in the licensed marketplace.

He manifested his vision in the form of a phenotype mega-hunt, a type of biological scavenger hunt in which he and a team of subject matter experts, including scientists, cultivators, and breeders, launched a maniacally challenging and detailed search for the best and the brightest of the cannabis genome.

Thus was born the first phenotype mega-hunt in the heart of Humboldt County, widely recognized as the epicenter of outdoor cannabis cultivation in the United States (and home to an estimated 20,000 cannabis farms). This ambitious project began with 40,000 select cultivars, all unique seeds that were grown in a variety of environments for the special project, including open fields, greenhouses (some employing leading-edge light deprivation), and indoor gardens.

“Choosing the best out of 30 is different than choosing the best from 40,000,” said Pennington. He and his team narrowed their candidate field to 10,000 ideal females, from which they selected only the highest quality 0.5 percent of flowering plants. That involved he and his team carefully examining and disqualifying 200 plants for each they labeled a finalist. The group then systematically discarded 90 percent of the 500 to derive 50 top-shelf “winners.”

Phenotypic Variation

Cannabis breeders speak a language all their own. Their obsession with phenotypes, terpene profiles, and liquid chromatography testing knows no bounds. However, to appreciate the significance of a project such as Pennington’s phenotype mega-hunt, one need not possess a Ph.D. in molecular genetics.

Phenotypic variation is a topic near and dear to botanical geneticists and breeders seeking to create heartier and more robust plants of any type, including cannabis. Breeders and farmers naturally seek genetics in the form of seeds and clone plants that yield more cannabis resin or that feature larger volumes of particular molecules, such as cannabidiol (CBD) and tetrahydrocannabinol (THC).

However, modern legal cannabis breeders and craft cultivators desire many genetic characteristics other than large volumes of the infamously psychoactive molecule THC. These traits include resilience to disease, tolerance for harsh weather, and ample production of specific constituent chemicals, including non-psychoactive CBD and the more than 200 terpenes and 113 cannabinoids within the cannabis genome.

Tropical Paradise. PHOTO | Humboldt Seed Company

Data-Driven Genetics Research

Pennington emphasized the serious nature of the genetics research behind the phenotype mega-hunt and his personal mission to preserve and build upon the generations of cannabis breeding expertise that exists in the Emerald Triangle.

“Folks don’t come to us because we post cool videos of sports cars to YouTube or are mentioned by the latest rapper,” said Pennington. “Our customers seek us because we provide genetics that truly perform. Last year, we took the California clone community by storm with our Blueberry Muffin that we crossed in 2008, named in 2010, and have been stabilizing and fine-tuning ever since.”

Pennington emphasized the need for cultivators and the entire industry to recognize the relatively primitive state of the science of cannabis genetics knowledge in an effort to continually push the research envelope and improve breeding techniques.

HSC decided not to restrict access to the selected phenotypes that resulted from the 2018 phenotype mega-hunt. “If this project created 50 premium clone strains in 2018, why would we not do that again in 2019 and do an even better job?” said Pennington.

In the world of cannabis genetics, his ambitious vision aligns with the reality of science: The knowledge gained from the distinct population crosses of his first phenotype mega-hunt will serve to expedite future efforts. “Knowing that it’s a make or break situation for many of the state’s small farms, we felt a moral obligation not to restrict access to the best cannabis strains,” Pennington continued.

Phenotype Mega-Hunt and the Quest for Rare Strains

According to Pennington, the holy grail of cannabis breeding is the discovery and exploitation of rare genetic traits in an effort to develop new and stable cultivars. The overall goal is to develop strains capable of delivering to consumers novel medical efficacy, wellness benefits, or lifestyle enhancement.

When he began considering the state of the cannabis genome, Pennington knew that he needed to start fresh with a traditional breeding strategy to discover this plant’s true capabilities, outside the limits of prohibition and its disorganized underground markets. “We bring distinct, distant populations together in breeding to examine their ‘phenotypic array.’ Essentially, DNA reproduction loves new DNA! It loves DNA it hasn’t seen before…or for millennia,” he said.

Industrious organizations such as Humboldt Seed Company are discovering and combining rare cannabis genetics in the hope of producing traits and benefits that haven’t been seen. “As much as we’ll find things that are appealing, we’ll find things that are very unappealing,” said Pennington.

The pioneering cannabis genetics researcher completed our interview by offering some sage advice to those who might consider similar projects: “This isn’t for the weak-at-heart farmer. It’s a tremendous amount of work and diligence involving massive data collection and analysis. But it’s totally necessary to target and craft the most beneficial cultivars for the dual benefits of commercial viability and medicinal efficacy.”

When queried about the future of the Northern California’s legal adult use cannabis cultivation industry, Pennington assumed a pensive, yet optimistic, stance. “To survive, I think we must be as innovative as possible. Innovation is an area where the companies with the deep pockets don’t necessarily have an advantage.”

Health

Iowa Medical Cannabis Board Backs Removing Patient Sales Tax

Iowa’s advisory board has backed seven medical cannabis recommendations, including ending patient sales tax. Legislative action would still be needed.

Published

on

Iowa State Capitol in Des Moines, with its gold central dome, smaller domes and green lawn

Iowa’s Medical Cannabidiol Board has backed removing sales tax from medical cannabis purchases, placing patient cost among its recommendations for the state’s next legislative discussion. The board voted November 6; the recommendation became the subject of new reporting November 13.

Patients should not read the vote as a tax exemption already available at the dispensary. The board advises policymakers. Its recommendation still needs to move through the process that changes Iowa law before it can alter what a customer owes.

The Marijuana Herald reported that Iowa Health and Human Services spokeswoman Danielle Sample confirmed seven unanimously approved recommendations in an email to that publication. Those proposals range from tax treatment and terminology to prescribing oversight and the products the program permits.

Patient cost moves onto the policy agenda

Removing sales tax would address one component of the amount a patient pays. It would not, by itself, set a product’s base price, lower the program’s registration fee or guarantee a particular amount of household savings.

That distinction is especially relevant in a medical program where participation has its own administrative costs. The state’s patient guidance currently lists a $100 application fee, with a $25 fee for eligible applicants. Cards expire after one year. Those are separate requirements from sales tax on purchases.

A patient comparing the proposal with today’s expenses therefore has several different numbers to consider: registration, the price of the product and tax. A recommendation about one should not be presented as a reform of all three.

The board’s November meeting presentation also put participation in context. It showed 17,974 active patients in January and 17,698 in September, a decline of about 1.5 percent. Those figures describe enrollment at two points; they do not establish why people joined, left or bought less cannabis.

Seven recommendations, with different consequences

The November 6 presentation, prepared by HHS cannabis regulation bureau chief Owen Parker and available in a copy hosted by an Iowa advocacy organization, lists the seven recommendations. Alongside eliminating patient sales tax, the board backed renaming Chapter 124E the Medical Cannabis Act.

The terminology proposal would align the law’s name more directly with the program’s subject. Renaming a statute, however, is distinct from expanding the products available under it. The board also reaffirmed its opposition to raw flower, so the package should not be mistaken for a recommendation to create a flower market.

Two further recommendations address tax equality for licensed businesses and a federal exemption related to potential rescheduling. Those concern the industry’s legal and financial environment. They are separate from the proposed exemption at the patient checkout, even though all involve the economics of medical cannabis.

The remaining recommendations concern prescribers’ access to patient purchase histories and oversight of telemedicine. Access to records and remote care can affect how a program operates, but the board’s vote does not itself supply a new prescribing procedure for patients to follow today.

What Iowa currently allows

The state’s patient guidance describes a program built around authorized preparations rather than raw cannabis flower. It lists vaporizable cartridges and concentrates, oral and sublingual forms such as tablets and tinctures, and topical preparations. It identifies raw flower for combustion or smoking and certain edible products as prohibited.

That existing framework helps explain why the board’s flower position matters. A tax recommendation can be significant for patients while leaving the range of authorized products unchanged. A lower checkout burden and broader product choice are different policy decisions.

Participation also requires certification and a state application. HHS identifies several eligible practitioner types, including physicians, physician assistants and advanced registered nurse practitioners. The recommendation package does not replace those current entry requirements or create automatic eligibility for anyone who wants to buy cannabis.

Where the proposal goes from here

HHS describes the board’s role as advisory and requires an annual report by January 1. Its membership includes eight physicians and one law enforcement representative. The department’s calendar independently confirms the November 6 meeting date.

The next meaningful development will be a legislative proposal or another formal action that translates a recommendation into enforceable language. Until then, the accurate description is that the board supports removing patient sales tax, rather than that Iowa has removed it.

For readers following our coverage of state cannabis rulemaking, the distinction is familiar: an official vote can move policy forward without opening a new service or changing a consumer’s rights immediately. Iowa patients have a concrete cost proposal to watch, with its practical effect still dependent on what lawmakers do next.

Stock view of the Iowa State Capitol in Des Moines; not the November 6 board meeting. Photo: Pixabay / Pexels.

Continue Reading

Science

Massachusetts Wants Cannabis Labels to Show When Flower Has Been Remediated

A proposed testing overhaul would make remediation more visible to Massachusetts cannabis shoppers. The rules still need public comment and final adoption.

Published

on

Two cannabis buds resting on a vinyl record

Massachusetts cannabis shoppers could eventually see a new distinction on product labels: whether the cannabis they are buying has been sanitized or remediated. It is one of the most consumer-facing elements of a testing overhaul that the Cannabis Control Commission advanced on November 12.

The decision moves draft regulations forward; it does not put a new label requirement into effect this weekend. The commission expects another draft approval in December, public comment in January and final promulgation in April 2027. Its proposed six-month implementation period would put the new testing framework into operation around October, if that timetable holds.

The Marijuana Herald covered the development November 13, following the commission’s announcement the previous day.

A processing history shoppers could actually see

In its November 12 announcement, the commission included labeling for products that have undergone sanitization or remediation. That would bring information about treatment closer to the point of purchase, where consumers already compare cannabinoid numbers, package sizes and prices.

Those details answer different questions. A potency figure describes cannabinoid concentration. A remediation disclosure describes part of a product’s processing history. Neither should be treated as a substitute for the other, and a disclosure alone would not establish that a particular product is unsafe.

The practical value is visibility. A customer could ask what treatment was used and why, rather than having to infer processing history from a brand name or a high THC percentage. The final wording, placement and implementation requirements will matter because a disclosure is useful only if buyers can recognize and understand it.

Failed tests would get an automatic second look

The commission also advanced a requirement for laboratories to automatically retest failures before issuing a certificate, with the stated aim of distinguishing an actual regulatory failure from a laboratory error. That is a proposed quality-control step, not permission for retailers to sell a failed batch while waiting for a better result.

The same package would require compliance testing before business-to-business as well as business-to-consumer sales. For shoppers, that is largely an upstream safeguard: testing obligations would attach before cannabis moves through commercial transactions, rather than being considered only at the final retail counter.

The draft further shifts microbial testing toward identifying specified organisms. The choice of what a laboratory measures is consequential. A test can be technically precise while still answering a narrower question than a consumer imagines when reading that a product has been tested.

These changes appear within a larger proposed testing framework, 935 CMR 503. The October meeting materials provide background on that work; the November announcement sets out the commission’s latest direction. The documents should be read as stages of rulemaking, rather than interchangeable descriptions of rules already in force.

Why the THC number is part of the background

Massachusetts has already confronted a separate question about how well potency labels match independent measurements. In an audit released August 13, the commission examined 63 flower products from 62 producers. Thirteen fell outside the state’s acceptable range of 75 to 125 percent of labeled potency.

That range is relative to the label claim, not a 75-percent THC minimum. For a product labeled 15 percent THC, the commission illustrated an acceptable range of 11.25 to 18.75 percent. Reading those numbers correctly matters before drawing conclusions about a package.

The audit was a defined sample, not proof that every Massachusetts product was inaccurately labeled. Nor is the November rulemaking announcement a new blanket recall. Together, however, the two developments show why laboratory reliability and the information reaching consumers are both on the commission’s agenda.

The next consequential step is public comment

The proposed overhaul would also eliminate the Standards Laboratory license type. Further work on sampling and pesticides is expected in 2027, which means this package should not be described as the final resolution of every testing issue in the market.

For now, consumers can follow the commission’s testing and analysis information and distinguish current requirements from proposed changes. Laboratories and licensees will need to examine the actual final text before treating the projected implementation date as a firm deadline.

The rulemaking is separate from the commission’s tentative timetable for cannabis lounge applications. Both concern the market’s next stage, but they regulate different activities. For the everyday shopper, the testing proposal’s clearest promise is more understandable information about the cannabis inside the package.

The January comment period would give patients, adult-use shoppers and businesses a chance to question those details before final adoption. Someone concerned about label clarity could focus on the disclosure language; a laboratory could address the retesting process. Those are concrete issues to evaluate when the next draft becomes available.

Stock photograph of cannabis flower; not a Massachusetts product or testing facility. Photo: Elsa Olofsson / Unsplash.

Continue Reading

Cannabis

Charlotte’s Web Reports Lower CBD Sales but a Narrower Quarterly Operating Loss

The hemp-derived CBD company’s latest results show why lower revenue and an improving quarterly loss can coexist—and why neither resolves the policy outlook.

Published

on

Empty amber glass bottles arranged on a light surface

Charlotte’s Web reported a difficult sales quarter for its hemp-derived CBD business while narrowing its operating loss. Revenue for the three months ended September 30, 2026 was US$9.4 million, down 18.3 percent from a year earlier. Its operating loss narrowed to US$3.7 million from US$5.3 million, showing why the direction of sales and the direction of a loss do not always match.

The company announced the results November 12 and filed its quarterly report with the U.S. Securities and Exchange Commission. The release attributes weaker revenue primarily to California restrictions that took effect in July, reduced promotional discounting and softer demand in parts of the hemp-wellness market. Those explanations are management’s account of the quarter, rather than an independent measurement of every factor affecting CBD shoppers.

Less revenue does not automatically mean a larger loss

The company’s earnings release reports quarterly gross profit of about US$4.4 million, compared with US$4.5 million a year earlier, even as sales fell. Gross margin improved to 46.9 percent from 38.9 percent. Selling, general and administrative expenses declined to US$8.1 million from US$9.7 million.

A percentage margin and a dollar profit measure answer different questions. A company can retain a larger share of each sales dollar while bringing in fewer dollars overall. Lower expenses can then narrow the operating loss without putting the business into operating profit. That is the distinction these results require.

The announcement also identifies an inventory reserve linked to simplifying the product range. Readers should therefore resist interpreting a single margin percentage as a permanent new baseline. Product mix, pricing, manufacturing costs and inventory adjustments can all affect the calculation.

The quarterly filing keeps the periods straight

The Form 10-Q records quarterly revenue more precisely at US$9.393 million and a net loss of US$3.458 million. These rounded to the US$9.4 million revenue and US$3.5 million net loss in the announcement. An operating loss and a net loss are different lines of the accounts, not conflicting reports of one number.

The nine-month picture is also distinct from the latest quarter. The release reports a US$20.7 million net loss for the first nine months, including noncash items associated with the earlier debenture conversion. It would be misleading to describe an improved third-quarter operating loss as proof that every year-to-date earnings measure improved.

The filing shows US$11.364 million of cash and cash equivalents at September 30. Cash on that date is a financial-position measure, rather than sales or profit earned during the quarter. Looking at the income statement and cash-flow statement together gives a fuller picture than treating a positive cash balance as evidence of profitability.

Hemp policy remains part of the business story

Cannabis policy is directly relevant to this CBD company because the legal definition of hemp determines which products can use that route to market. The Congressional Research Service’s October 28 legal sidebar explains that the federal delay does not move every element of the new definition to the same date. It distinguishes the treatment of certain cannabinoids not naturally produced by the plant from provisions delayed until December 11.

That distinction is useful beyond one company. A hemp-derived label does not settle a product’s future legal status, and a federal deadline does not automatically override a state’s separate rules. Consumers and businesses need to identify the applicable product definition, ingredients and jurisdiction.

Charlotte’s Web’s October 28 announcement said it planned to hold a corporate update after December 11 rather than a November earnings call, seeking greater policy clarity before discussing its outlook. That is a communications plan, not evidence that Congress will produce the outcome the company prefers.

Product access and medical evidence are separate

A financial report from a CBD business does not establish that a product treats a disease or is appropriate for a particular person. Sales trends describe commercial activity. They do not measure a clinical benefit, and a discussion of future healthcare distribution should not be mistaken for a new drug approval or a general reimbursement entitlement.

Our coverage of Willie Nelson’s hemp-policy appeal addresses the public debate over access. Charlotte’s Web’s results supply a different perspective: how a company says restrictions, pricing decisions and expenses are affecting its accounts. The two stories illuminate different parts of the same policy uncertainty.

The next meaningful business signals will include the durability of any sales recovery, spending levels and the details of the legal framework actually in force. For now, the results show a smaller quarterly operating loss alongside lower CBD revenue. They do not yet resolve whether the company can turn that improvement into sustained growth and profitability.

Illustrative empty-bottle stock photograph; not Charlotte’s Web packaging or identified CBD products. Photo: Kelly Sikkema / Unsplash.

Continue Reading

Trending

Join The Cannabis Aficionado Community!
Join the Cannabis Aficionado community and receive all of the most relevant news geared towards our sophisticated enthusiast community.
Loading

Copyright ©️ 2026 Cannabis Aficionado. Cannabis Aficionado is a registered trademark of CNM Inc. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service, Privacy Policy and Cookies Policy. People may receive compensation for some links to products and services. Offers may be subject to change without notice.